Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to -$3000.0.

  • Journey Medical's Other Non Operating Income fell 10026.67% to -$3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$71000.0, marking a year-over-year decrease of 10663.55%. This contributed to the annual value of $1.1 million for FY2024, which is 71475.41% up from last year.
  • Journey Medical's Other Non Operating Income amounted to -$3000.0 in Q3 2025, which was down 10026.67% from -$61000.0 recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Other Non Operating Income peaked at $1.1 million during Q3 2024, and registered a low of -$263000.0 during Q4 2021.
  • Its 5-year average for Other Non Operating Income is $18800.0, with a median of -$32000.0 in 2024.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 100000.0% in 2022, then surged by 121386.14% in 2024.
  • Journey Medical's Other Non Operating Income (Quarter) stood at -$263000.0 in 2021, then surged by 74.52% to -$67000.0 in 2022, then skyrocketed by 97.01% to -$2000.0 in 2023, then surged by 56350.0% to $1.1 million in 2024, then plummeted by 100.27% to -$3000.0 in 2025.
  • Its Other Non Operating Income stands at -$3000.0 for Q3 2025, versus -$61000.0 for Q2 2025 and -$7000.0 for Q1 2025.